Share This Article:

Short Hydration in Chemotherapy with Cisplatin plus S-1 for Advanced or Recurrent Gastric Cancer: A Retrospective Study

Full-Text HTML XML Download Download as PDF (Size:275KB) PP. 1254-1261
DOI: 10.4236/jct.2015.615137    3,570 Downloads   3,939 Views  

ABSTRACT

Background: Despite there are a few reports that assessed the S-1 + CDDP regimen with short hydration regimen for unresectable or metastatic gastric cancer, there is no consensus on the best regimen for short hydration. The aim of study was to evaluate the safety and the efficacy of S-1 plus cisplatin doublet chemotherapy with short hydration. Methods: S-1 was administered orally (p.o.) twice daily for the first 3 weeks of a 5-week cycle. Dose of S-1 administered was calculated according to the body surface area. CDDP was given as an intravenous (i.v.) infusion of 60 mg/m2 on day 8 of each cycle. Patients received the total of 1900 ml infusion containing 1000 ml of acetate Ringer’s solution as pre- and post-hydraion. 300 ml of 20% mannitol was administered as a diuretic. Results: 35 patients with unresectable or recurrent gastric cancer were enrolled. The reasons for termination of S-1 + CDDP were as follows: 21 (63.6%) by progressive disease; 12 (31.4%) by toxicity. Even though 12 of 35 patients (34.2%) were discontinued S-1 + CDDP chemotherapy, only one patient was discontinued by Grade 2 of increased creatinine. TTF (time to progression) was 174 days (3 - 586 days), and the median of the total number of treatment cycles of S-1 + CDDP was 3.31. Median overall survival, as secondary endpoint, was 518 days. Conclusions: Our study suggested that the short hydration regimen is as safe and efficient as the continuous hydration regimen.

Cite this paper

Tsuji, A. , Negoro, Y. , Okita, Y. , Kotaka, M. , Nishiuchi, T. , Kotake, T. , Satake, H. and Hatachi, Y. (2015) Short Hydration in Chemotherapy with Cisplatin plus S-1 for Advanced or Recurrent Gastric Cancer: A Retrospective Study. Journal of Cancer Therapy, 6, 1254-1261. doi: 10.4236/jct.2015.615137.

References

[1] Tanaka, M., Ma, E., Tanaka, H., Ioka, A., Nakahara, T. and Takahashi, H. (2012) Trends of Stomach Cancer Mortality in Eastern Asia in 1950-2004: Comparative Study of Japan, Hong Kong and Singapore Using Age, Period and Cohort Analysis. International Journal of Cancer, 130, 930-936.
http://dx.doi.org/10.1002/ijc.26080
[2] Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., Takiuchi, H., Nasu, J. and Ohtsu, A. (2009) Gastrointestinal Oncology Study Group of the Japan Clinical Oncology G: Fluorouracil versus Combination of Irinotecan plus Cisplatin versus S-1 in Metastatic Gastric Cancer: A Randomised Phase 3 Study. The Lancet Oncology, 10, 1063-1069.
http://dx.doi.org/10.1016/S1470-2045(09)70259-1
[3] Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., Toh, Y., Nagaie, T., Takagi, S., Yamamura, Y., Yanaoka, K., Orita, H. and Takeuchi, M. (2008) S-1 plus Cisplatin versus S-1 Alone for First-Line Treatment of Advanced Gastric Cancer (Spirits Trial): A Phase III Trial. The Lancet Oncology, 9, 215-221.
http://dx.doi.org/10.1016/S1470-2045(08)70035-4
[4] Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., European Society for Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO) and European Society of Radiotherapy and Oncology (ESTRO) (2013) Gastric Cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, 57-63.
http://dx.doi.org/10.1093/annonc/mdt344
[5] Mor, V., Stalker, M.Z., Gralla, R., Scher, H.I., Cimma, C., Park, D., Flaherty, A.M., Kiss, M., Nelson, P., Laliberte, L., et al. (1988) Day Hospital as an Alternative to Inpatient Care for Cancer Patients: A Random Assignment Trial. Journal of Clinical Epidemiology, 41, 771-785.
http://dx.doi.org/10.1016/0895-4356(88)90164-3
[6] Horinouchi, H., Kubota, K., Itani, H., Taniyama, T.K., Nakamichi, S., Wakui, H., Kanda, S., Nokihara, H., Yamamoto, N., Sekine, I. and Tamura, T. (2013) Short Hydration in Chemotherapy Containing Cisplatin (>/=75 mg/m2) for Patients with Lung Cancer: A Prospective Study. Japanese Journal of Clinical Oncology, 43, 1105-1109.
http://dx.doi.org/10.1093/jjco/hyt122
[7] Ouchi, A., Asano, M., Aono, K., Watanabe, T. and Kato, T. (2014) Comparison of Short and Continuous Hydration Regimen in Chemotherapy Containing Intermediate- to High-Dose Cisplatin. Journal of Oncology, 2014, Article ID: 767652.
http://dx.doi.org/10.1155/2014/767652
[8] Okazaki, S., Nakajima, T.E., Hashimoto, J., Yamamoto, S., Takahari, D., Kato, K., Hamaguchi, T., Yamada, Y., Shimada, Y. and Tamura, K. (2013) A Feasibility Study of Outpatient Chemotherapy with s-1 + Cisplatin in Patients with Advanced Gastric Cancer. Gastric Cancer, 16, 41-47.
http://dx.doi.org/10.1007/s10120-012-0139-4
[9] Satake, H., Tsuji, A., Kotake, T. and Fujita, M. (2014) Feasibility of Outpatient Chemotherapy with S-1 and Cisplatin for Gastric Cancer. Journal of Cancer Therapy, 5, 759-765.
http://dx.doi.org/10.4236/jct.2014.58084
[10] Kitazaki, T., Fukuda, Y., Fukahori, S., Oyanagi, K., Soda, H., Nakamura, Y. and Kohno, S. (2015) Usefulness of antiemetic Therapy with Aprepitant, Palonosetron, and Dexamethasone for Lung Cancer Patients on Cisplatin-Based or Carboplatin-Based Chemotherapy. Supportive Care in Cancer, 23, 185-190.
http://dx.doi.org/10.1007/s00520-014-2339-4
[11] Longo, F., Mansueto, G., Lapadula, V., Stumbo, L., Del Bene, G., Adua, D., De Filippis, L., Bonizzoni, E. and Quadrini, S. (2012) Combination of Aprepitant, Palonosetron and Dexamethasone as Antiemetic Prophylaxis in Lung Cancer Patients Receiving Multiple Cycles of Cisplatin-Based Chemotherapy. International Journal of Clinical Practice, 66, 753-757.
http://dx.doi.org/10.1111/j.1742-1241.2012.02969.x

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.